Substituted Benzoimidazodiazepines Targeting GABAAR Subtypes for Airway Relaxation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchoconstrictive diseases like asthma lack effective pharmacologic approaches for acute airway smooth muscle relaxation, with limited options beyond β-adrenoceptor agonists and anti-cholinergics, and existing therapies do not adequately target GABAAR subtypes in airway smooth muscle and immune/inflammatory cells.
Innovation Solution
Development of novel compounds that selectively target the α4 and α5 subunits of GABAARs, acting as allosteric modulators with reduced benzodiazepine-type CNS effects, which can be administered to relax airway smooth muscle contraction and reduce lung inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds that alter GABAAR function are used to treat bronchoconstrictive diseases, then airway smooth muscle relaxation is achieved, but benzodiazepine-type CNS effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that confer selective affinity for GABAAR subtypes expressed in airway smooth muscle cells rather than those in the CNS. This subtype selectivity enables the drug to produce local therapeutic effects in the airways while minimizing systemic CNS penetration and associated side effects.
Solution Approach 2:
The patent segments the GABAAR receptor family into distinct subtypes (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1-3) and develops compounds that selectively target specific subtypes. By segmenting the therapeutic approach to focus on airway-relevant subtypes rather than all GABAARs, the invention achieves airway relaxation while reducing off-target CNS effects.
2Adaptability or versatility
If existing treatments like β-adrenoceptor agonists and anti-cholinergics are used, then acute airway constriction is treated, but therapeutic options remain limited
Solution Approach 1:
The patent introduces a novel therapeutic mechanism by targeting GABAARs, which are not traditionally associated with airway smooth muscle relaxation. This multi-functional approach expands the pharmacologic toolkit for treating bronchoconstrictive diseases beyond the conventional β-adrenoceptor agonists and anti-cholinergics, providing a new class of bronchodilators with different mechanisms of action.
3Reliability
If compounds with broad GABAAR activity are used, then airway smooth muscle relaxation occurs, but selectivity for airway-specific GABAAR subtypes is reduced
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that confer selective affinity for GABAAR subtypes expressed in airway smooth muscle cells rather than those in the CNS. This subtype selectivity enables the drug to produce local therapeutic effects in the airways while minimizing systemic CNS penetration and associated side effects.
Solution Approach 2:
The patent employs feedback mechanisms in the drug design process by iteratively optimizing compound structures based on their binding affinity profiles across different GABAAR subtypes. Through structure-activity relationship studies and selective binding assessments, the compounds are refined to enhance airway subtype selectivity while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention describes substituted benzo[f]imidazo[1,5-a][1,4]diazepines of the formula (I):wherein R1, R2, R2′, R3, and X are as disclosed herein. These compounds target alpha-4 and alpha-5 GABAa receptors and are useful for the treatment of airway hyperresponsiveness and inflammation in asthma.